K. Dalhoff (Lubeck, Germany), J. Lorenz (Luedenscheid, Germany)
Antimycobacterial and antipseudomonas drug from allium ascalonicum M. Amin, M. A. Tabee (Ahwaz, Islamic Republic Of Iran)
|   |
Thoracic hydatid cyst in a growing country: management and outcome I. Zendah, S. Bacha, S. Merai, S. Ben Mrad, F. Tritar (Ariana, Tunisia)
|   |
The impact of toxocariasis in patients with multiple patchy pulmonary infiltrations in Korea Y. S. Yoon, S. Y. Kwon, H. I. Yoon, J. H. Lee, C. T. Lee (Seoul, Seongnam, Republic Of Korea)
|   |
Thoracic rupture of hepatic hydatidosis I. Sifi, J. Cherif, A. Zouaoui, N. Mehiri, B. Louzir, M. Beji, J. Daghfous (Tunis, Tunisia)
|   |
Clinical caracteristics of pulmonary actinomycosis: 10 years‘ follow up L. Nagorni Obradovic, J. Stojsic, D. Subotic (Belgrade, Serbia And Montenegro)
|   |
The effect of NO synthesis modulators on calcium accumulation and neutrophil apoptosis during the community-acquired pneumonia T. V. Zhavoronok, Y. V. Starikov, T. S. Ageeva, N. V. Ryazanceva, E. A. Stepovaya, V. A. Bychkov, G. V. Petina, S. P. Mishustin (Tomsk, Russian Federation)
|   |
Differential diagnostics of community acquired pneumonia and thrombembolia of pulmonary artery distal branches T. S. Ageeva, N. G. Krivonogov, F. F. Tetenev, A. V. Dubodelova, S. P. Mishustin (Tomsk, Russian Federation)
|   |
Severe community acquired pneumonia: clinical and aetiological evaluation O. El-Shinawy, H. Makhlouf, L. Hassan, H. Rashed (Assiut, Egypt)
|  |
Particularities of community-acquired pneumonia in the elderly S. M. Maalej, A. C. Chorfa, A. C. Chtourou, M. B. Bourguiba, H. F. Fennira, A. B. K. Ben Kheder, I. D. Drira (Tunis, Tunisia)
|   |
Activated protein C protection in endotoxin-induced lung injury is mediated by lung matrix metalloproteinases activity M. Albertini, F. Pirrone, C. Pastore, S. Paltrinieri, G. Sironi, P. Riccaboni, S. Pellecchia, M. Viola, A. Passi, M. G. Clement (Milan, Varese, Italy)
|   |
Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD A. Romanovskikh, A. Sinopalnikov, S. Ratchina (Moscow, Smolensk, Russian Federation)
|  |
Pleural complications of pulmonary hydatid disease H. Daghfous, J. BenAmar, I. Zendah, S. Merai, S. BenMrad, F. Tritar (Ariana, Tunisia)
|   |
Diagnostics of chlamydia pneumoniae infection in patients with bronchial asthma V. Halinska, Y. Mostovoy, H. Demchuk, N. Slepchenko, M. Ovcharuk, N. Tsymbalyuk (Vinnytsya, Ukraine)
|  |
Cases applying emergency department with infectious symptoms and their infectious agents D. Tatar, G. Senol, C. Anar, A. K. Cirak, G. Tibet (Izmir, Turkey)
|   |
An analysis of non-effective empiric antibacterial therapy in COPD acute exacerbation L. Konopkina (Dnipropetrovs‘k, Ukraine)
|   |
The usage of laferon in treatment of patients with community acquired pneumonia (CAP) I. Ilyuk, S. Nechiporuk (Vinnitsa, Ukraine)
|  |
Usefulness of shock index in severity assessment of community-acquired pneumonia P. Myint, S. Vowler, F. Alobeidi, S. Tariq (King‘s Lynn, Cambridge, United Kingdom)
|   |
Recurrent pulmonary hydatid disease cases S. Arinc, L. Alpay, E. Okur, O. Sogukpinar, A. Kosif, M. Coban, S. Halezeroglu, A. Atasalihi (Istanbul, Turkey)
|   |
The impact of patients‘ age and concomitant diseases on community-acquired pneumonia outcome M. Djuric, D. Povazan, N. Secen (Sremska Kamenica, Serbia And Montenegro)
|  |